<?xml version="1.0" encoding="UTF-8"?>
<iati-activities version="2.03">
 <iati-activity default-currency="USD" hierarchy="1" humanitarian="0" iati-activities:version="2.03" xml:lang="EN" xmlns:iati-activities="http://d-portal.org/xmlns/iati-activities">
  <iati-identifier>SE-0-SE-29-2013-6588_1-238-12263</iati-identifier>
  <reporting-org ref="SE-0" secondary-reporter="0" type="10">
   <narrative xml:lang="EN">Sweden</narrative>
  </reporting-org>
  <title>
   <narrative xml:lang="EN">Enhancing the immune response against tuberculosis - from bench to bedside</narrative>
   <narrative xml:lang="SV">Stimulering av immunsvaret vid tuberkulos - fr&#xE5;n experiment till klinik</narrative>
  </title>
  <description type="1">
   <narrative xml:lang="SV">Tuberkulos &#xE4;r v&#xE4;rldens mest spridda infektionssjukdom. N&#xE4;rmare en tredjedel av jordens befolkning &#xE4;r smittade och 1,2 miljoner d&#xF6;r varje &#xE5;r i sjukdomen. Trots vaccination, effektiv antibiotikabehandling och f&#xF6;rb&#xE4;ttrade socioekonomiska f&#xF6;rh&#xE5;llanden, &#xF6;kar sjukdomen idag. En orsak &#xE4;r urbaniseringen i fr.a. Afrika, en annan &#xE4;r HIV utvecklingen som &#xF6;kar k&#xE4;nsligheten f&#xF6;r aktiv tuberkulos. En tredje orsak &#xE4;r den &#xF6;kade resistensutvecklingen som ocks&#xE5; sker i industrialiserade l&#xE4;nder, fr.a. &#xD6;steuropa. Det beh&#xF6;vs d&#xE4;rf&#xF6;r nya effektivare insatser f&#xF6;r att f&#xF6;rhindra en fortsatt spridning av denna sjukdom. Omfattande forskning sker nu f&#xF6;r att utveckla nya effektivare vacciner som i f&#xF6;rsta hand kan komplettera nuvarande BCG vaccination. Men traditionell vaccination r&#xE4;cker inte f&#xF6;r att skydda oss mot tuberkulos. Vi har st&#xE4;llt oss fr&#xE5;gan varf&#xF6;r *bara* 5-10% av alla de som smittas inte blir sjuka. Fr&#xE5;gan &#xE4;r hur kroppens naturliga (medf&#xF6;dda) immunitet skyddar oss mot denna infektion, och hur den kan f&#xF6;rst&#xE4;rkas. Hur kan vi stimulera kroppens skydd mot tuberkulos? N&#xE4;r kroppens inflammatoriska celler ansamlas i lungan och d&#xE4;r &#xE4;ter upp och avd&#xF6;dar tuberkelbakterier, sker ocks&#xE5; programmerad celld&#xF6;d (apoptos) och aktivering av lungans immunceller som nu bildar inflammationsstimulerande och bakterieavd&#xF6;dande &#xE4;mnen, bl.a. kv&#xE4;veoxid (NO). I det fortsatta arbetet studerar vi hur aktiveringen av dessa celler sker och vilka egenskaper hos tuberkelbakterien som medverkar i denna process. P&#xE5; basis av dessa grundl&#xE4;ggande studier, genomf&#xF6;r vi kliniska studier i Etiopien, d&#xE4;r vi utvecklar strategier f&#xF6;r att f&#xF6;rst&#xE4;rk immunf&#xF6;rsvaret hos patienter med tuberkulos. Vi har tidigare visat att tillskott av aminosyran arginin och jordn&#xF6;tter, som inneh&#xE5;ller h&#xF6;ga m&#xE4;ngder arginin, p&#xE5;skyndar tillfrisknandet hos patienter med TB. Detta beror p&#xE5; an &#xF6;kad lokal produktion av NO. Aktuella studier visar vidare att samtidig HIV/TB infektion st&#xF6;r bildningen av NO i lungan, vilket &#xF6;kar k&#xE4;nsligheten f&#xF6;r infektion. Vi breddar nu dessa nutritionsinriktade studier med att f&#xF6;lja TB patienter som &#xE4;r dubbelinfekterade med HIV eller mask. H&#xE4;r &#xE4;r m&#xE5;let att f&#xF6;rst&#xE5; varf&#xF6;r dessa patienter l&#xF6;per &#xF6;kad risk att utveckla tuberkulos, och d&#xE4;rmed kunna f&#xF6;rebygga att sjukdomen bryter ut. Genom en kombination av grundl&#xE4;ggande infektionsimmunologiska och kliniska studier av tuberkulos i endemiska omr&#xE5;den, hoppas vi kunna utveckla nya strategier f&#xF6;r hur tuberkulossjukdomen kan f&#xF6;rebyggas och behandlas.</narrative>
   <narrative xml:lang="EN">We are building our present research efforts on several important observations related to the innate immune response to Mtb: (i) apoptotic cells and Hsp72 facilitate the pro-inflammatory response and antimicrobial capacity in Mtb-infected macrophages, and antigen presentation in dendritic cells (DC) (ii) susceptibility for nitric oxide (NO) among clinical Mtb strains correlates to INH resistance and clinical outcome; and (iii) arginine stimulates NO production in the lung of patients with tuberculosis and HIV, and facilitates treatment and protection against the disease. . Using a translational approach our goal is to find a strategy to modulate and stimulate the innate immune response, thereby strengthening macrophage capacity in individuals exposed to Mtb and coinfecting agents (HIV, helminths) in endemic areas, and shorten the duration of disease. Specific aims to achieve this are (i) to characterize how apoptotic cells and Hsp72 activate macrophages; (ii) to identify how polymorphisms in the inflammasome genes affect susceptibility to Mtb infection; (iii) how coinfections with HIV or helminths affect macrophage capacity to handle Mtb; (iv) to evaluate how stimulation of NO production and anti-helminth treatment can enhance macrophage function, and serve as adjuvant treatment to conventional chemotherapy. This translational project links basic infectious biology knowhow to clinical applications in high burden TB areas like Ethiopia and Peru.</narrative>
  </description>
  <participating-org ref="51000" role="4" type="80">
   <narrative xml:lang="EN">Link&#xF6;pings universitet</narrative>
  </participating-org>
  <participating-org ref="SE-0" role="1" type="10">
   <narrative xml:lang="EN">Sweden</narrative>
  </participating-org>
  <participating-org ref="SE-29" role="3" type="10">
   <narrative xml:lang="EN">The Swedish Research Council</narrative>
  </participating-org>
  <activity-status code="4"></activity-status>
  <activity-date iso-date="2014-01-01" type="2"></activity-date>
  <activity-date iso-date="2016-12-31" type="4"></activity-date>
  <contact-info>
   <organisation>
    <narrative xml:lang="EN">The Swedish Research Council</narrative>
   </organisation>
   <telephone>+46 8 546 44 000</telephone>
   <email>vetenskapsradet@vr.se</email>
   <website>www.vr.se</website>
   <mailing-address>
    <narrative xml:lang="EN">Box 1035, 101 38 Stockholm, Sweden</narrative>
   </mailing-address>
  </contact-info>
  <recipient-country code="ET" percentage="100">
   <narrative xml:lang="EN">Ethiopia</narrative>
  </recipient-country>
  <sector code="122" percentage="100" vocabulary="2">
   <narrative xml:lang="EN">Basic Health</narrative>
  </sector>
  <sector code="12263" percentage="100" vocabulary="1">
   <narrative xml:lang="EN">Tuberculosis control</narrative>
  </sector>
  <policy-marker code="5" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Aid Targeting the Objectives of the Convention on Biological Diversity</narrative>
  </policy-marker>
  <policy-marker code="8" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Aid Targeting the Objectives of the Convention to Combat Desertification</narrative>
  </policy-marker>
  <policy-marker code="7" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Aid Targeting the Objectives of the Framework Convention on Climate Change - Adaptation</narrative>
  </policy-marker>
  <policy-marker code="6" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Aid Targeting the Objectives of the Framework Convention on Climate Change - Mitigation</narrative>
  </policy-marker>
  <policy-marker code="2" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Aid to Environment</narrative>
  </policy-marker>
  <policy-marker code="11" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Disability</narrative>
  </policy-marker>
  <policy-marker code="10" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Disaster Risk Reduction(DRR)</narrative>
  </policy-marker>
  <policy-marker code="1" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Gender Equality</narrative>
  </policy-marker>
  <policy-marker code="3" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Participatory Development/Good Governance</narrative>
  </policy-marker>
  <policy-marker code="9" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Reproductive, Maternal, Newborn and Child Health (RMNCH)</narrative>
  </policy-marker>
  <policy-marker code="4" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Trade Development</narrative>
  </policy-marker>
  <collaboration-type code="1"></collaboration-type>
  <default-flow-type code="10"></default-flow-type>
  <default-finance-type code="110"></default-finance-type>
  <default-aid-type code="D02" vocabulary="1"></default-aid-type>
  <default-tied-status code="4"></default-tied-status>
  <budget>
   <period-start iso-date="2014-01-01"></period-start>
   <period-end iso-date="2014-12-28"></period-end>
   <value currency="USD" value-date="2014-01-01">55831.7176635228</value>
  </budget>
  <budget>
   <period-start iso-date="2015-01-01"></period-start>
   <period-end iso-date="2015-12-28"></period-end>
   <value currency="USD" value-date="2015-01-01">40810.0316752281</value>
  </budget>
  <budget>
   <period-start iso-date="2016-01-01"></period-start>
   <period-end iso-date="2016-12-28"></period-end>
   <value currency="USD" value-date="2016-01-01">40203.3541751885</value>
  </budget>
  <transaction>
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2013-11-07"></transaction-date>
   <value currency="USD" value-date="2013-11-07">328870.6012405576</value>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2014-01-28"></transaction-date>
   <value currency="USD" value-date="2014-01-28">55831.7176635228</value>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2015-01-28"></transaction-date>
   <value currency="USD" value-date="2015-01-28">40809.7944076021</value>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2016-01-28"></transaction-date>
   <value currency="USD" value-date="2016-01-28">40203.3541751885</value>
  </transaction>
  <crs-add>
   <other-flags code="1" significance="1"></other-flags>
  </crs-add>
  <sida:contribution xmlns:sida="http://sida.se/ns/contribution#"></sida:contribution>
 </iati-activity>
</iati-activities>
